Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27714650 | 0.89 | NOTUM (0.55) | HRH3NOTUMALDH1A1MAPTMAPK1 | |
| SCHEMBL8133600 | 0.86 | HRH3 (0.50) | HRH3NOTUMALDH1A1MAPTMAPK1 | |
| SCHEMBL1816609 | 0.83 | NOTUM (0.41) | HRH3NOTUMDEGS1CYP3A4CYP2C19 | |
| SCHEMBL10642901 | 0.81 | ADRB1 (0.53) | ALDH1A1MAPTNPSR1 | |
| SCHEMBL14862764 | 0.81 | LTA4H (0.45) | HRH3 | |
| SCHEMBL27624590 | 0.81 | HRH3 (0.52) | HRH3NOTUMALDH1A1MAPTMAPK1 | |
| SCHEMBL6694318 | 0.81 | HTR3E (0.53) | NOTUMALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL3301450 | 0.81 | BPTF (0.54) | HRH3NOTUMALDH1A1MAPTMAPK1 | |
| SCHEMBL520612 | 0.81 | MAPT (0.50) | ALDH1A1MAPTMAPK1LMNAHTT | |
| SCHEMBL2046676 | 0.81 | SLC6A2 (0.49) | ALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952300-B | 5-or 8-substituted imidazo [1,5-a ] pyridines | 百济神州有限公司 | 2022-01-18 | — | — | CN | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3371196-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIV MONTREAL (CA) | 2021-10-27 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-10919874-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (KY) | 2021-02-16 | — | — | US | disclosed |
| US-20190382370-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2019-12-19 | — | — | US | disclosed |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10370354-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (KY) | 2019-08-06 | — | — | US | disclosed |
| CN-109952300-A | As indoleamine 2, imidazo [1,5-a] pyridine of the novel 5 or 8- substitution of 3- dioxygenase enzyme and/or tryptophan 2,3- dioxygenase enzyme selectivity inhibitor | 百济神州有限公司 | 2019-06-28 | — | — | CN | disclosed |
| US-9309273-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013090210-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | disclosed |
| EP-0915881-A1 | PYRROLOAZEPINE COMPOUNDS | SUNTORY LIMITED (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998041527-A1 | PYRROLOAZEPINE COMPOUNDS | SUNTORY LIMITED (JP) | 1998-09-24 | — | — | WO | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| EP-0291244-A1 | Cyclic carbamate derivatives | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | HRH3 2899/4885NOTUM 770/4885ALDH1A1 1342/4885 |
| US-20190382370-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GAA, GPX1 | HRH3 4545/4885NOTUM 998/4885ALDH1A1 330/4885 |
| US-10919874-B2 | Metalloenzyme inhibitor compounds | MMEL1, GAA, GPX1 | HRH3 4545/4885NOTUM 998/4885ALDH1A1 330/4885 |
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | CHUK, IKBKB, IKBKE | HRH3 3750/4885NOTUM 2834/4885ALDH1A1 4380/4885 |
| US-10370354-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | HRH3 4559/4885NOTUM 1126/4885ALDH1A1 289/4885 |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | HRH3 2899/4885NOTUM 770/4885ALDH1A1 1342/4885 |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | HRH3 4559/4885NOTUM 1126/4885ALDH1A1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.